{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tamoxifen+60+mg&page=2",
    "query": {
      "intervention": "Tamoxifen 60 mg",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 25,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tamoxifen+60+mg&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tamoxifen+60+mg&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-07T10:30:11.321Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00723398",
      "title": "Nutritional Supplements and Hormonal Manipulations for Breast Cancer Prevention",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Lovaza 4gm oral",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Raloxifene 60 Mg Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "Raloxifene 30 Mg Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "Lovaza 4gm & Raloxifene 30mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "DRUG"
      ],
      "sponsor": "Milton S. Hershey Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "70 Years",
        "sex": "FEMALE",
        "summary": "35 Years to 70 Years · Female only"
      },
      "enrollment_count": 266,
      "start_date": "2009-03",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2018-11-01",
      "last_synced_at": "2026-10-07T10:30:11.321Z",
      "location_count": 1,
      "location_summary": "Hershey, Pennsylvania",
      "locations": [
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00723398"
    },
    {
      "nct_id": "NCT06195306",
      "title": "Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Atypical Hyperplasia",
        "Breast Carcinoma",
        "Breast Ductal Carcinoma In Situ",
        "Breast Lobular Carcinoma In Situ"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Mammography",
          "type": "PROCEDURE"
        },
        {
          "name": "Omega-3-Acid Ethyl Esters",
          "type": "DRUG"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Random Periareolar Fine-Needle Aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "Tamoxifen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "74 Years",
        "sex": "FEMALE",
        "summary": "45 Years to 74 Years · Female only"
      },
      "enrollment_count": 66,
      "start_date": "2025-07-28",
      "completion_date": "2028-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-04",
      "last_synced_at": "2026-10-07T10:30:11.321Z",
      "location_count": 3,
      "location_summary": "Kansas City, Kansas • Ann Arbor, Michigan • Columbus, Ohio",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06195306"
    },
    {
      "nct_id": "NCT06944145",
      "title": "New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "BPH (Benign Prostatic Hyperplasia)",
        "Lower Urinary Track Symptoms"
      ],
      "interventions": [
        {
          "name": "raloxifene",
          "type": "DRUG"
        },
        {
          "name": "Finasteride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Beth Israel Deaconess Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 242,
      "start_date": "2025-12-03",
      "completion_date": "2030-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-23",
      "last_synced_at": "2026-10-07T10:30:11.321Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06944145"
    },
    {
      "nct_id": "NCT00670319",
      "title": "Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Osteoporosis, Postmenopausal"
      ],
      "interventions": [
        {
          "name": "Raloxifene HCL",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "80 Years",
        "sex": "FEMALE",
        "summary": "Up to 80 Years · Female only"
      },
      "enrollment_count": 7705,
      "start_date": "1994-11",
      "completion_date": "1999-09",
      "has_results": false,
      "last_update_posted_date": "2008-05-01",
      "last_synced_at": "2026-10-07T10:30:11.321Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00670319"
    },
    {
      "nct_id": "NCT05296798",
      "title": "A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Locally Advanced or Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Phesgo",
          "type": "DRUG"
        },
        {
          "name": "Giredestrant",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "LHRH Agonist",
          "type": "DRUG"
        },
        {
          "name": "Optional Endocrine Therapy of Investigator's Choice",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 922,
      "start_date": "2022-07-18",
      "completion_date": "2030-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-02",
      "last_synced_at": "2026-10-07T10:30:11.321Z",
      "location_count": 10,
      "location_summary": "Tucson, Arizona • Los Angeles, California • Jacksonville, Florida + 7 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Annapolis",
          "state": "Maryland"
        },
        {
          "city": "Germantown",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05296798"
    },
    {
      "nct_id": "NCT00431444",
      "title": "Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Osteoporosis"
      ],
      "interventions": [
        {
          "name": "Raloxifene",
          "type": "DRUG"
        },
        {
          "name": "Zoledronic acid",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral pills",
          "type": "DRUG"
        },
        {
          "name": "Placebo intravenous (i.v.) infusion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "80 Years",
        "sex": "FEMALE",
        "summary": "45 Years to 80 Years · Female only"
      },
      "enrollment_count": 110,
      "start_date": "2007-01",
      "completion_date": "2008-07",
      "has_results": true,
      "last_update_posted_date": "2011-03-29",
      "last_synced_at": "2026-10-07T10:30:11.321Z",
      "location_count": 17,
      "location_summary": "Phoenix, Arizona • Buena Park, California • Washington D.C., District of Columbia + 12 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Buena Park",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00431444"
    },
    {
      "nct_id": "NCT00774267",
      "title": "Study Evaluating Changes In Mammographic Breast Density",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Osteoporosis"
      ],
      "interventions": [
        {
          "name": "BZA 20 mg/CE 0.45 mg",
          "type": "DRUG"
        },
        {
          "name": "BZA 20 mg/CE 0.625 mg",
          "type": "DRUG"
        },
        {
          "name": "Raloxifene 60 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "FEMALE",
        "summary": "40 Years to 75 Years · Female only"
      },
      "enrollment_count": 507,
      "start_date": "2009-01",
      "completion_date": "2010-04",
      "has_results": true,
      "last_update_posted_date": "2014-04-08",
      "last_synced_at": "2026-10-07T10:30:11.321Z",
      "location_count": 22,
      "location_summary": "Fort Myers, Florida • Gainesville, Florida • New Port Richey, Florida + 19 more",
      "locations": [
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "New Port Richey",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00774267"
    },
    {
      "nct_id": "NCT05101564",
      "title": "Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "HER2-negative Breast Cancer",
        "ER Positive Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Alpelisib",
          "type": "DRUG"
        },
        {
          "name": "Tamoxifen",
          "type": "DRUG"
        },
        {
          "name": "Zotatifin",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jennifer Lee Caswell-Jin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2023-03-20",
      "completion_date": "2024-06-03",
      "has_results": true,
      "last_update_posted_date": "2026-02-12",
      "last_synced_at": "2026-10-07T10:30:11.321Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05101564"
    },
    {
      "nct_id": "NCT03493854",
      "title": "A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Early Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pertuzumab IV",
          "type": "DRUG"
        },
        {
          "name": "FDC of Pertuzumab and Trastuzumab SC",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab IV",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab SC",
          "type": "DRUG"
        },
        {
          "name": "Surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Post-operative Radiotherapy",
          "type": "RADIATION"
        },
        {
          "name": "Hormone Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 500,
      "start_date": "2018-06-14",
      "completion_date": "2023-06-02",
      "has_results": true,
      "last_update_posted_date": "2024-06-26",
      "last_synced_at": "2026-10-07T10:30:11.321Z",
      "location_count": 4,
      "location_summary": "Rockville, Maryland • Farmington, New Mexico • Charlotte, North Carolina + 1 more",
      "locations": [
        {
          "city": "Rockville",
          "state": "Maryland"
        },
        {
          "city": "Farmington",
          "state": "New Mexico"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Lakewood",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03493854"
    },
    {
      "nct_id": "NCT00847821",
      "title": "Observational Study Analyzing RNA Expression Of Endometrial Biopsy Samples From Placebo, Bazedoxifene/Conjugated Estrogens And Raloxifene",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Postmenopause"
      ],
      "interventions": [
        {
          "name": "Bazedoxifene 10 mg/CE 0.625 mg",
          "type": "DRUG"
        },
        {
          "name": "Bazedoxifene 20 mg/CE 0.625 mg",
          "type": "DRUG"
        },
        {
          "name": "Bazedoxifene 40 mg/CE 0.625 mg",
          "type": "DRUG"
        },
        {
          "name": "Bazedoxifene 10 mg/CE 0.45 mg",
          "type": "DRUG"
        },
        {
          "name": "Bazedoxifene 20 mg/CE 0.45 mg",
          "type": "DRUG"
        },
        {
          "name": "Bazedoxifene 40 mg/CE 0.45 mg",
          "type": "DRUG"
        },
        {
          "name": "Raloxifene 60 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wyeth is now a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "FEMALE",
        "summary": "40 Years to 75 Years · Female only"
      },
      "enrollment_count": 185,
      "start_date": "2009-05",
      "completion_date": "2010-08",
      "has_results": false,
      "last_update_posted_date": "2010-09-06",
      "last_synced_at": "2026-10-07T10:30:11.321Z",
      "location_count": 22,
      "location_summary": "Fort Myers, Florida • Gainesville, Florida • New Port Richey, Florida + 19 more",
      "locations": [
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "New Port Richey",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00847821"
    }
  ]
}